The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Sai-Lan Liu; Xue-Song Sun; Xiao-Yun Li; Lin-Quan Tang; Qiu-Yan Chen; Huan-Xin Lin; Yu-Jing Liang; Jin-Jie Yan; Chao Lin; Shan-Shan Guo; Li-Ting Liu; Yang Li; Hao-Jun Xie; Qing-Nan Tang; Hu Liang; Ling Guo; Hai-Qiang Mai

doi:10.1186/s40880-019-0357-9

Table 5 Multivariable analysis of prognostic factors of 68 NPC patients with positive postoperative pathological results

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Variable	PFS		OS		DMFS		LRRFS		LRFS		RRFS
Variable	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age	0.948 (0.458–1.962)	0.885	1.365 (0.501–3.719)	0.543	0.505 (0.164–1.555)	0.234	0.750 (0.336–1.676)	0.483	0.662 (0.231–1.895)	0.442	1.097 (0.412–2.917)	0.853
Sex	0.866 (0.401–1.871)	0.715	0.506 (0.160–1.600)	0.246	0.652 (0.192–2.208)	0.492	0.568 (0.248–1.302)	0.182	0.595 (0.202–1.752)	0.346	0.489 (0.176–1.360)	0.171
T stage	2.733 (1.139–6.557)	0.024	4.523 (1.240–16.501)	0.022	11.418 (2.406–54.182)	0.002	1.616 (0.633–4.126)	0.315	1.473 (0.441–4.923)	0.529	2.985 (0.900–9.894)	0.074
N stage	2.070 (0.555–7.726)	0.279	2.852 (0.564–14.409)	0.205	8.385 (1.213–57.978)	0.031	1.380 (0.339–5.617)	0.653	2.054 (0.303–13.919)	0.461	2.979 (0.528–16.798)	0.216
Clinical stage	0.593 (0.240–1.463)	0.256	1.183 (0.369–3.790)	0.777	0.361 (0.086–1.515)	0.164	0.696 (0.285–1.697)	0.425	0.467 (0.132–1.651)	0.237	0.621 (0.192–2.008)	0.426
EBV DNA before first treatment	1.166 (0.553–2.459)	0.687	0.812 (0.287–2.295)	0.695	1.296 (0.287–0.423)	0.650	1.762 (0.770–4.033)	0.180	0.868 (0.300–2.510)	0.793	3.631 (1.013–13.019)	0.048
Preoperative EBV DNA	1.589 (0.768–3.290)	0.212	3.501 (1.075–11.398)	0.037	2.051 (0.688–6.119)	0.197	1.575 (0.732–3.389)	0.246	2.588 (0.926–7.234)	0.070	1.827 (0.684–4.882)	0.229
Treatment for NPC	1.341 (0.800–2.247)	0.266	1.621 (0.684–3.845)	0.273	3.367 (1.081–10.489)	0.036	1.120 (0.657–1.910)	0.677	0.840 (0.461–1.531)	0.569	2.184 (0.874–5.459)	0.095

NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, HR hazard ratio, CI confidence interval
All variables were transformed into categorical variables. HRs were calculated for age (≥ 45 vs. < 45 years), sex (male vs. female), T stage (3–4 vs. 1–2), N stage (3 vs. 1–2), clinical stage (IV vs. III vs. II), EBV DNA before first treatment (> 4000 vs. ≤ 4000 copies/mL), preoperative EBV DNA (> 0 vs. 0 copy/mL), and treatment for NPC (RT vs. CCRT vs. NAC + CCRT vs. CCRT + AC)

Back to article page